Michael Dudley
Fondateur chez Rempex Pharmaceuticals, Inc.
Profil
Michael N.
Dudley is the founder of Rempex Pharmaceuticals, Inc. which was founded in 2011, where he holds the title of CSO, Senior Vice President-Research & Development.
He is currently the President, Chief Executive Officer & Director at Qpex Biopharma, Inc. Dr. Dudley's former positions include Vice President-Pharmacology & Microbiology at Essential Therapeutics, Inc., Vice President-Preclinical & Clinical Sciences at Diversa Corp., and Chief Scientific Officer at MPEX Pharmaceuticals, Inc. Dr. Dudley received a doctorate degree from The University of California, San Francisco.
Postes actifs de Michael Dudley
| Sociétés | Poste | Début |
|---|---|---|
Rempex Pharmaceuticals, Inc.
 Rempex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Rempex Pharmaceuticals, Inc. develops new therapies to combat the growing issue of antibiotic resistance. It focuses on the discovery and development of new antibacterial drugs to meet the clinical need created by multi-drug resistant bacterial pathogens. The company was founded by Daniel Burgess, Michael Dudley and Jeffery Loutit in June 2011 and is headquartered in San Diego, CA. | Fondateur | 01/06/2011 |
Qpex Biopharma, Inc.
 Qpex Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Qpex Biopharma, Inc. develops a pipeline of agents addressing critical needs for the treatment of infectious diseases in the inpatient and outpatient settings. The company is headquartered in San Diego, CA. | Directeur Général | - |
Anciens postes connus de Michael Dudley
| Sociétés | Poste | Fin |
|---|---|---|
Diversa Corp.
 Diversa Corp. Miscellaneous Commercial ServicesCommercial Services Diversa searches high and low for DNA. In its quest to develop new enzymes and other active biological compounds, the biotechnology company collects and catalogs the DNA of organisms in diverse environments (from manure piles to tropical islands). A variety of manufacturers license these compounds from the firm to develop or improve their products, which include detergents, oils, animal feeds, and pharmaceuticals. Diversa's products include enzymes for the oil and gas industry | Directeur Technique/Scientifique/R&D | 10/11/2011 |
Essential Therapeutics, Inc.
 Essential Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Essential Therapeutics, Inc. manufactures pharmaceutical goods for viral and fungal infections | Corporate Officer/Principal | - |
MPEX Pharmaceuticals, Inc.
 MPEX Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services MPEX Pharmaceuticals, Inc. develops and manufactures therapies for antibiotic resistance with focus on gram-negative organisms. It offers Aeroquin (MP- 376), an aerosol formulation of levofloxacin for the treatment of pulmonary infections in patients with cystic fibrosis, as well as antibiotic programs to address antibiotic resistance in gram negative organisms. The company was founded in 2001 and is headquartered in San Diego, CA. | Directeur Technique/Scientifique/R&D | - |
Formation de Michael Dudley
| The University of California, San Francisco | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 5 |
|---|---|
Essential Therapeutics, Inc.
Essential Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Essential Therapeutics, Inc. manufactures pharmaceutical goods for viral and fungal infections | Health Technology |
Diversa Corp.
Diversa Corp. Miscellaneous Commercial ServicesCommercial Services Diversa searches high and low for DNA. In its quest to develop new enzymes and other active biological compounds, the biotechnology company collects and catalogs the DNA of organisms in diverse environments (from manure piles to tropical islands). A variety of manufacturers license these compounds from the firm to develop or improve their products, which include detergents, oils, animal feeds, and pharmaceuticals. Diversa's products include enzymes for the oil and gas industry | Commercial Services |
MPEX Pharmaceuticals, Inc.
MPEX Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services MPEX Pharmaceuticals, Inc. develops and manufactures therapies for antibiotic resistance with focus on gram-negative organisms. It offers Aeroquin (MP- 376), an aerosol formulation of levofloxacin for the treatment of pulmonary infections in patients with cystic fibrosis, as well as antibiotic programs to address antibiotic resistance in gram negative organisms. The company was founded in 2001 and is headquartered in San Diego, CA. | Commercial Services |
Rempex Pharmaceuticals, Inc.
Rempex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Rempex Pharmaceuticals, Inc. develops new therapies to combat the growing issue of antibiotic resistance. It focuses on the discovery and development of new antibacterial drugs to meet the clinical need created by multi-drug resistant bacterial pathogens. The company was founded by Daniel Burgess, Michael Dudley and Jeffery Loutit in June 2011 and is headquartered in San Diego, CA. | Health Technology |
Qpex Biopharma, Inc.
Qpex Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Qpex Biopharma, Inc. develops a pipeline of agents addressing critical needs for the treatment of infectious diseases in the inpatient and outpatient settings. The company is headquartered in San Diego, CA. | Health Technology |
